ISO 17034:
Catalog Number : CS-O-13215
CAS Number : 259793-96-9
Status : Available for immediate dispatch
List Price Online Price Size Stock Status Quantity

Custom Quote

Send us a request for Custom
pack size and pricing.

Synthesis Advice

Schedule a call with our Experts to
answer your questions.

Instant Help

Connect with our Live Chat
representatives for instant help.

What is the Chemical Information of Favipiravir?

Chemical Name : Favipiravir
Category : API Standards
Molecular Weight : 157.10 mol/g
Molecular Formula : C₅H₄FN₃O₂
Therapeutic : COVID19

Shipping & Availability

Status : Available for immediate dispatch
[Login Needed]
[Login Needed]
Hazardous Compound : No

More Information

Payment mode : Credit / Debit / Purchase Order
Taxes : All prices are inclusive taxes
Refund Policy : 30 days money back guarantee
Canonical SMILES : C1=C(N=C(C(=O)N1)C(=O)N)F
Isomeric SMILES : C1=C(N=C(C(=O)N1)C(=O)N)F
InChI : InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
IUPAC Name : 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
Exact Mass : 157.02875454
Melting Point : 187℃ to 193℃
Solubility : slightly soluble in water
Hazard Class : Acute Tox. 4 (66.67%)
Description : Favipiravir is a member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan. It has a role as an antiviral drug, an anticoronaviral agent and an EC (RNA-directed RNA polymerase) inhibitor. It is a primary carboxamide, a hydroxypyrazine and an organofluorine compound.
EC Number : 856-840-0
Toxicity Summary : Based on single-dose toxicity studies, the lethal dose for oral and intravenous favipiravir in mice is estimated to be >2000 mg/kg. In rats, the lethal dose for oral administration is >2000 mg/kg, while the lethal dose in dogs and monkeys is >1000 mg/kg. Symptoms of overdose appear to include but are not limited to reduced body weight, vomiting, and decreased locomotor activity. In repeat-dose toxicity studies involving dogs, rats, and monkeys, notable findings after administration of oral favipiravir included: adverse effects on hematopoietic tissues such as decreased red blood cell (RBC) production, and increases in liver function parameters such as aspartate aminotransferase (AST), alkaline phosphatase (ALP), alanine aminotransferase (ALT) and total bilirubin, and increased vacuolization in hepatocytes. Testis toxicity was also noted. Favipiravir is known to be teratogenic; therefore, administration of favipiravir should be avoided in women if pregnancy is confirmed or suspected. Toxicity information regarding favipiravir in humans is not readily available.